Actinogen Medical Limited · ASX:ACW
Actinogen Medical — Investor Presentation (March 2017)
23 slides from Actinogen Medical's investor presentation, March 2017
Slide 1: Investor Presentation
INVESTOR PRESENTATION Dr Bill Ketelbey CEO March 2017
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Actinogen Medical Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to mak
Slide 3: Overview
OVERVIEW 3
Slide 4: A Devastating Disease
A A lzheimer’s disease is the leading cause of death in the UK and Europe and the second leading DEVASTATING cause of death in Australia. DISEASE Of the top-ten leading fatal illnesses, it remains the only one that cannot be prevented, treated or cured. Drugs available to treat Alzheimer's disease p
Slide 5: Corporate Overview
CORPORATE OVERVIEW Actinogen Medical (ASX:ACW) is focused on an innovative approach for treating Alzheimer's STOCK METRICS* disease and cognitive impairment in chronic neurodegenerative diseases, through the inhibition of cortisol production. • The Company is developing Xanamem™, a novel drug for tr
Slide 6: A Simple but Compelling Story
A SIMPLE BUT COMPELLING STORY 1 2 3 4 5 Xanamem™ - a Independent research Human trial of cortisol Xanamem™ Phase I human trials novel therapy for shows a strong inhibition in the brain demonstrated a confirm that Xanamem™ Alzheimer's disease that association between demonstrates cognitive significan
Slide 7: Board of Directors
BOARD OF DIRECTORS DR GEOFF BROOKE CHAIRMAN Dr Brooke is a clinically trained physician turned venture capitalist with over 30 years' experience in the healthcare investment industry. He was the founder and managing director of two venture capital firms, Medvest Inc and GBS Venture Partners. GBS is
Slide 8: Xanamem Clinical Advisory Board
XANAMEMTM CLINICAL ADVISORY BOARD PROFESSOR CRAIG RITCHIE (CHAIR) Professor Ritchie is a world-leading authority on dementia and has been a senior investigator on more than 30 drug trials of both disease-modifying and symptomatic agents for the condition. Professor Ritchie is leading the PREVENT pro
Slide 9: Market Opportunity and About Xanamem
MARKET OPPORTUNITY AND ABOUT XANAMEM™ 9
Slide 10: Alzheimer's Disease: A Vast Unmet Medical Need
ALZHEIMER’S DISEASE: A VAST UNMET MEDICAL NEED • There are nearly 50 million Alzheimer's disease sufferers world-wide and the number is set to double every 20 years. • It’s the leading cause of death in the UK and second only to heart disease in Australia. • Of the top-ten leading fatal illnesses, A
Slide 11: Why There Is Vast Market Potential for Xanamem
WHY THERE IS VAST MARKET POTENTIAL FOR XANAMEM™ • The incidence and cost of treating Alzheimer’s is growing rapidly. Management of Alzheimer's will swamp available budgets. • There are currently only four approved drugs to treat Alzheimer’s, none of which modify the underlying disease and only provi
Slide 12: The Current State of AD Drugs in Development
THE CURRENT STATE OF AD DRUGS IN DEVELOPMENT • There are around 100 different compounds in human research for Alzheimer's disease. • Xanamem is only one of two cortisol inhibitors under development. • Xanamem will be used in combination with other drugs under development. • Xanamem is an oral medica
Slide 13: About Xanamem
ABOUT XANAMEMTM Actinogen Medical’s research candidate, Xanamem™, is a novel drug under development for the treatment of Alzheimer’s disease. • Research has demonstrated that increased cortisol, also known as the “stress hormone”, is associated with cognitive impairment, the development of beta- amy
Slide 14: Validation
VALIDATION CORTISOL and ALZHEIMER’S: • A number of recent independent studies support the association between cortisol and the development and progression of Alzheimer's disease. (Geerlings et al 2015, Lehallier et al 2015, Popp et al 2015, Ennis et al 2017, Peitrzak et al 2017) • Some of the most c
Slide 15: Clinical Development
CLINICAL DEVELOPMENT 15
Slide 16: Historical Timeline
HISTORICAL TIMELINE Carbenoxolone is shown to 11ẞ-HSD1 is highly enhance cognitive function expressed in regions in elderly men and type II important for diabetics S TA R T Xanamem™ cognition (Sandeep et al., 2004) data publication 11ẞ-HSD1 First First Xanamem™ and enzyme patent human crosses blood
Slide 17: XanADu Phase II Trial
XANADU PHASE II TRIAL Phase II double blind, randomised, placebo-controlled study to assess the efficacy and safety of Xanamem™ in participants with mild Alzheimer's disease XanamemTM treatment course 12 weeks 174 Mild Alzheimer’s patients XanamemTM 10mg daily for 12 weeks Vs Trial conducted at 20 s
Slide 18: Diseases Being Targeted with Xanamem
DISEASES BEING TARGETED WITH XANAMEMTM PRE-CLINICAL PHASE I PHASE II Alzheimer’s disease Diabetes cognitive impairment Post traumatic stress disorder Post myocardial infarction 18
Slide 19: Valuation and Outlook
VALUATION AND-OUTLOOK ye , ~ f . y}
Slide 20: Peer Comparison
PEER COMPARISON What big pharma 2000 companies are paying 1800 for acquisition of drug 1600 VALUE US$ MILLIONS developers in the 1400 Alzheimer’s space X 1200 1000 800 X 600 X 400 200 0 PH I PH II PH III 20
Slide 21: Xanamem's Journey of Discovery
XANAMEM™’S JOURNEY OF DISCOVERY Diabetes Cognition Phase II 11β-HSD1 is highly expressed in regions XanADu First Subject In important for cognition Xanamem™ data Carbenoxolone is shown to enhance published cognitive function in Webster et al., 2017 11β-HSD1 elderly men and First First Xanamem™ XanAD
Slide 22: Investment Summary
INVESTMENT SUMMARY Huge unmet medical Novel approach: The Multiple Potential XanamemTM has a Highly experienced need: The total cost of association between Indications: Actinogen long patent life: Board and Alzheimer’s to rise to $US cortisol and Alzheimer’s has identified a number Xanamem has manag
Slide 23: Contact
CONTACT: DR. BILL KETELBEY CEO & Managing Director ☏ Main: +61 2 8964 7401 ✉Email: [email protected]
Actinogen Medical — Investor Presentation (March 2017) on 6ix